Oregon Public Employees Retirement Fund Acquires 33 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Oregon Public Employees Retirement Fund increased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 0.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 9,108 shares of the biotechnology company’s stock after purchasing an additional 33 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in United Therapeutics were worth $3,214,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. GraniteShares Advisors LLC bought a new position in United Therapeutics during the 4th quarter worth about $442,000. Denali Advisors LLC acquired a new position in shares of United Therapeutics during the fourth quarter worth about $495,000. Los Angeles Capital Management LLC grew its holdings in shares of United Therapeutics by 14.4% during the fourth quarter. Los Angeles Capital Management LLC now owns 103,597 shares of the biotechnology company’s stock worth $36,553,000 after buying an additional 13,030 shares in the last quarter. Amalgamated Bank raised its position in United Therapeutics by 2.8% in the 4th quarter. Amalgamated Bank now owns 22,167 shares of the biotechnology company’s stock valued at $7,821,000 after buying an additional 602 shares during the last quarter. Finally, Colonial River Investments LLC lifted its stake in United Therapeutics by 12.7% in the 4th quarter. Colonial River Investments LLC now owns 1,367 shares of the biotechnology company’s stock valued at $482,000 after acquiring an additional 154 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Up 1.5 %

NASDAQ:UTHR opened at $323.62 on Friday. United Therapeutics Co. has a 12-month low of $221.53 and a 12-month high of $417.82. The firm has a market capitalization of $14.45 billion, a price-to-earnings ratio of 14.21, a P/E/G ratio of 0.97 and a beta of 0.57. The stock’s 50 day moving average price is $360.44 and its two-hundred day moving average price is $360.55.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping analysts’ consensus estimates of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. During the same period in the previous year, the firm earned $4.36 EPS. Equities research analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

Wall Street Analyst Weigh In

UTHR has been the subject of several research reports. UBS Group raised their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. LADENBURG THALM/SH SH raised their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Argus boosted their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Oppenheimer increased their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Finally, The Goldman Sachs Group lifted their target price on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $388.25.

Insider Buying and Selling at United Therapeutics

In other news, Director Louis W. Sullivan sold 26,209 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the sale, the director now owns 5,051 shares in the company, valued at $1,885,134.22. The trade was a 83.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 7,700 shares of the stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $374.37, for a total value of $2,882,649.00. Following the transaction, the executive vice president now owns 36,710 shares in the company, valued at approximately $13,743,122.70. This trade represents a 17.34 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 124,164 shares of company stock worth $45,278,893 over the last ninety days. Insiders own 11.90% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.